In the complex landscape of hematology and life-saving biologicals, Human Coagulation Factor VIII (FVIII) stands as a cornerstone therapy for Hemophilia A. As a premier Factor VIII supplier, Jiangxi Serum Pharma Industries Co., Ltd. understands that this is not merely a commodity, but a critical biological bridge for patients with clotting deficiencies. Our commitment to excellence is rooted in nearly a decade of rigorous pharmaceutical export experience, ensuring that every vial meets the stringent requirements of global healthcare systems.
Factor VIII is a large glycoprotein that acts as a cofactor for Factor IXa, which, in the presence of Ca2+ and phospholipids, converts Factor X to the activated form Xa. Without sufficient levels of functional FVIII, the coagulation cascade fails, leading to spontaneous or prolonged bleeding. Our role as a leading Factor VIII manufacturer and distributor is to ensure the purity, potency, and viral safety of this essential protein.
Jiangxi Serum Pharma Industries Co., Ltd. leverages 10 years of deep industry immersion to provide Information Gain that moves beyond basic supply. We provide:
The global pharmaceutical market has increasingly looked toward China as a primary hub for high-quality coagulation factor supply. This shift is driven by massive investments in biotechnology and a robust regulatory framework aligned with international standards. As a leading Factor VIII supplier from China, we capitalize on a vertically integrated supply chain that spans from plasma collection to advanced protein purification.
China possesses some of the world’s largest plasma fractionation facilities, enabling a stable and consistent supply of Factor VIII even during global shortages. This scale ensures cost-competitive pricing without compromising clinical efficacy.
Our partners utilize cutting-edge bio-fermentation and chromatography techniques. For recombinant FVIII, our facilities implement state-of-the-art mammalian cell culture systems (CHO or BHK lines) to produce proteins with human-like glycosylation patterns.
All products undergo rigorous testing according to the Chinese Pharmacopoeia (ChP), which is increasingly harmonized with the USP and EP, ensuring that our Factor VIII exports meet global safety thresholds.
For plasma-derived Factor VIII, the risk of transfusion-transmitted infections is mitigated through a rigorous three-tier safety strategy:
As a Factor VIII supplier committed to transparency, we provide batch-specific certificates of analysis (CoA) detailing specific activity levels—typically ranging from 50 to 150 IU/mg of protein before stabilization—ensuring clinical practitioners can calculate exact dosages for prophylaxis or emergency bleed management.
We provide full dossier support for local Ministry of Health (MoH) registrations, including stability data and clinical summary reports.
Factor VIII is temperature-sensitive. We utilize validated passive and active cooling systems (2°C to 8°C) with real-time GPS and temperature monitoring.
Our team is experienced in international government tenders, providing the necessary bank guarantees and long-term supply commitment letters.
Localized labeling in English, Spanish, French, or Arabic to comply with regional pharmaceutical labeling laws.
The industry is transitioning toward Extended Half-Life (EHL) factors and gene therapy. As a forward-looking Factor VIII supplier, Jiangxi Serum Pharma is already monitoring the development of Fc-fusion and PEGylated technologies that reduce the frequency of infusions from thrice weekly to once or twice weekly.
Furthermore, the emergence of non-factor therapies like Emicizumab has shifted the landscape. However, for acute bleeds and surgical interventions, FVIII remains the gold standard for immediate hemostasis. Our R&D partners are currently focusing on bio-fermentation improvements to enhance the stability of FVIII at room temperature, which would revolutionize access in developing regions with unreliable power grids.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
Serum Pharma will continuously monitor the development of the cutting-edge markets, currently cooperating on customization of Pre-Mix services.
Innovative stabilization techniques for pharmaceutical ingredients to improve bioavailability and shelf-life.
Advanced microbial fermentation processes for high-purity biological products and nutritional ingredients.
